Literature DB >> 32240779

Lumbar intervertebral disc mRNA sequencing identifies the regulatory pathway in patients with disc herniation and spondylolisthesis.

Mohamad Bydon1, F M Moinuddin2, Yagiz U Yolcu2, Waseem Wahood3, Mohammed Ali Alvi2, Anshit Goyal2, Mohammed Elminawy2, Catalina Galeano-Garces4, Amel Dudakovic5, Ahmad Nassr6, A Noelle Larson6, Andre J van Wijnen7.   

Abstract

Lumbar degenerative disc disease (DDD) is a multifaceted progressive condition and often accompanied by disc herniation (DH) and/or degenerative spondylolisthesis (DS). Given the high prevalence of the disease (up to 20% according to some estimates) and the high costs associated with its care, there is a need to explore novel therapies such as regenerative medicine. Exploring these novel therapies first warrants investigation of molecular pathways underlying these disorders. Here, we show results from next generation RNA sequencing (RNA-seq) on mRNA isolated from 10 human nucleus pulposus (NP) samples of lumbar degenerated discs (DH and DS; n = 5 for each tissue) and other musculoskeletal tissues (Bone, cartilage, growth plate, and muscle; n = 7 for each tissue). Pathway and network analyses based on gene ontology (GO) terms were used to identify the biological functions of differentially expressed mRNAs. A total of 701 genes were found to be significantly upregulated in lumbar NP tissue compared to other musculoskeletal tissues. These differentially expressed mRNAs were primarily involved in DNA damage, immunity and G1/S transition of mitotic cell cycle. Interestingly, DH-specific signaling genes showed major network in chemotactic (e.g., CXCL10, CXCL11, IL1RL2 and IL6) and matrix-degrading pathway (e.g., MMP16, ADAMTSL1, 5, 8, 12, and 15), while DS-specific signaling genes were found to be those involved in cell adhesion (e.g., CDH1, EPHA1 and EFNA2) and inflammatory cytokines (e.g., CD19, CXCL5, CCL24, 25 and XCL2). Our findings provide new leads for therapeutic drug discovery that would permit optimization of medical or pharmacological intervention for cases of lumbar DDD.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Degenerative disc disease; Lumbar spine; Nucleus pulposus; RNAseq; mRNA

Year:  2020        PMID: 32240779     DOI: 10.1016/j.gene.2020.144634

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  5 in total

1.  TAK-242 treatment and its effect on mechanical properties and gene expression associated with IVD degeneration in SPARC-null mice.

Authors:  Mitchel C Whittal; Sarah J Poynter; Kayla Samms; K Josh Briar; Sabrina I Sinopoli; Magali Millecamps; Laura S Stone; Stephanie J DeWitte-Orr; Diane E Gregory
Journal:  Eur Spine J       Date:  2022-07-11       Impact factor: 2.721

Review 2.  Systems neuroimmunology: a review of multiomics methodologies to characterize neuroimmunological interactions in spinal and cranial diseases.

Authors:  Cameron Zamanian; Archis R Bhandarkar; Dileep D Monie; F M Moinuddin; Richard G Vile; Alfredo Quiñones-Hinojosa; Mohamad Bydon
Journal:  Neurosurg Focus       Date:  2022-02       Impact factor: 4.332

3.  Microarray analysis reveals an inflammatory transcriptomic signature in peripheral blood for sciatica.

Authors:  Yi Wang; Guogang Dai; Ling Jiang; Shichuan Liao; Jiao Xia
Journal:  BMC Neurol       Date:  2021-02-03       Impact factor: 2.474

4.  Single-Cell RNA-Seq Analysis of Cells from Degenerating and Non-Degenerating Intervertebral Discs from the Same Individual Reveals New Biomarkers for Intervertebral Disc Degeneration.

Authors:  Hosni Cherif; Matthew Mannarino; Alain Sarabia Pacis; Jiannis Ragoussis; Oded Rabau; Jean A Ouellet; Lisbet Haglund
Journal:  Int J Mol Sci       Date:  2022-04-03       Impact factor: 5.923

5.  Constitutive activation of NF-κB inducing kinase (NIK) in the mesenchymal lineage using Osterix (Sp7)- or Fibroblast-specific protein 1 (S100a4)-Cre drives spontaneous soft tissue sarcoma.

Authors:  Jennifer L Davis; Roman Thaler; Linda Cox; Biancamaria Ricci; Heather M Zannit; Fei Wan; Roberta Faccio; Amel Dudakovic; Andre J van Wijnen; Deborah J Veis
Journal:  PLoS One       Date:  2021-07-22       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.